Cerity Partners LLC Buys 46,575 Shares of AstraZeneca PLC (NASDAQ:AZN)

Cerity Partners LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 30.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 199,425 shares of the company’s stock after buying an additional 46,575 shares during the quarter. Cerity Partners LLC’s holdings in AstraZeneca were worth $15,537,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of AstraZeneca during the third quarter valued at $234,000. Nwam LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter worth about $627,000. Meridian Wealth Management LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter worth about $1,005,000. Biltmore Family Office LLC bought a new position in AstraZeneca during the 3rd quarter valued at about $230,000. Finally, Charles Schwab Investment Management Inc. boosted its position in AstraZeneca by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,784,235 shares of the company’s stock valued at $139,010,000 after buying an additional 8,830 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. TD Cowen lifted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Trading Up 1.2 %

AZN stock opened at $66.40 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a market cap of $205.88 billion, a P/E ratio of 31.77, a PEG ratio of 1.20 and a beta of 0.47. The business has a fifty day moving average of $73.19 and a 200-day moving average of $77.72.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 EPS. As a group, equities research analysts expect that AstraZeneca PLC will post 4.1 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.